drugset / Trial / NCT06496217
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
NaSequentialOpen-labelBasic science
Summary
Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function
Timeline
- Start
- 2024-06-13
- Primary completion
- 2025-09-04
- Completion
- 2025-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canvuparatide | Protein / enzyme biologic | 900 ug | Subcutaneous |